tiprankstipranks
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
PremiumPress Releasesargenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
18d ago
argenx Announces Annual General Meeting of Shareholders on May 7, 2024
PremiumPress Releases
argenx Announces Annual General Meeting of Shareholders on May 7, 2024
19d ago
Argenx price target raised to $408 from $402 at Scotiabank
PremiumThe Fly
Argenx price target raised to $408 from $402 at Scotiabank
19d ago
Roche’s mixed myasthenia gravis data sending these stocks in opposite directions
PremiumThe FlyRoche’s mixed myasthenia gravis data sending these stocks in opposite directions
24d ago
Roche’s mixed myasthenia gravis data sending these stocks in opposite directions
PremiumThe Fly
Roche’s mixed myasthenia gravis data sending these stocks in opposite directions
24d ago
Immunovant rallies after Chugai myasthenia gravis study failure
PremiumThe Fly
Immunovant rallies after Chugai myasthenia gravis study failure
24d ago
Argenx price target lowered to EUR 490 from EUR 510 at JPMorgan
PremiumThe FlyArgenx price target lowered to EUR 490 from EUR 510 at JPMorgan
1M ago
Argenx price target raised to $440 from $370 at Truist
PremiumThe Fly
Argenx price target raised to $440 from $370 at Truist
1M ago
Argenx price target raised to $440 from $430 at Guggenheim
PremiumThe Fly
Argenx price target raised to $440 from $430 at Guggenheim
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100